Profile data is unavailable for this security.
About the company
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
- Revenue in AUD (TTM)74.87m
- Net income in AUD14.31m
- Incorporated1999
- Employees61.00
- LocationCogState LtdLevel 32, 367 Collins StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39664-1300
- Fax+61 39664-1301
- Websitehttps://cogstate.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cloudbreak Pharma Inc | 14.13m | -59.09m | 358.05m | 60.00 | -- | -- | -- | 25.35 | -0.3897 | -0.3897 | 0.0932 | -3.08 | -- | -- | -- | 1,532,275.00 | -- | -- | -- | -- | -- | -- | -418.33 | -- | -- | -- | 19.44 | -- | -- | -- | 23.40 | -- | -- | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 22.88m | -61.77m | 363.48m | 195.00 | -- | 3.14 | -- | 15.89 | -0.8687 | -0.8687 | 0.3214 | 1.48 | 0.148 | -- | 3,865.48 | 811,245.50 | -40.09 | -- | -51.56 | -- | -- | -- | -270.79 | -- | -- | -- | 0.2236 | -- | 19,109.59 | -- | 16.76 | -- | -- | -- |
| Cogstate Ltd | 74.87m | 14.31m | 370.56m | 61.00 | 26.26 | 5.40 | 20.07 | 4.95 | 0.0823 | 0.0823 | 0.4303 | 0.3999 | 0.866 | -- | 4.69 | -- | 16.55 | 11.82 | 20.98 | 16.38 | 60.53 | 56.32 | 19.11 | 14.87 | -- | -- | 0.0097 | -- | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Mabpharm Ltd | 86.51m | -5.61m | 372.73m | 383.00 | -- | 18.48 | 56.03 | 4.31 | -0.0075 | -0.0075 | 0.116 | 0.0271 | 0.4209 | 0.4659 | 4.05 | 1,519,346.00 | -2.73 | -19.62 | -4.02 | -25.69 | 86.40 | -- | -6.48 | -211.59 | 0.6906 | -1.58 | 0.7552 | -- | 196.27 | -- | 38.89 | -- | -12.13 | -- |
| Frontage Holdings Corp | 357.39m | 5.42m | 375.39m | 1.54k | 69.06 | 0.778 | 6.60 | 1.05 | 0.0148 | 0.0148 | 0.9734 | 1.31 | 0.4545 | 60.36 | 3.97 | 1,267,418.00 | 0.6902 | 3.05 | 0.8654 | 3.64 | 27.78 | 32.14 | 1.52 | 6.84 | 1.22 | 1.97 | 0.2861 | 0.00 | -1.90 | 20.48 | -92.68 | -46.72 | 13.29 | -- |
| Hanx Biopharmaceuticals (Wuhan) Co Ltd | -18.08bn | -18.08bn | 396.43m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.30 | -- | -- | -- |
| Heartseed Inc | 24.16m | 4.75m | 399.03m | 39.00 | 83.36 | 6.03 | 158.73 | 16.51 | 22.88 | 22.88 | 116.95 | 316.02 | 0.3697 | -- | 22.10 | 67,685,900.00 | 7.27 | -- | 7.61 | -- | -- | -- | 19.67 | -- | 20.40 | -- | 0.0003 | -- | 153.42 | -- | 44.84 | -- | -- | -- |
| Healios KK | 887.93k | -35.61m | 405.73m | 65.00 | -- | 15.07 | -- | 456.94 | -39.54 | -39.54 | 0.9577 | 25.42 | 0.0065 | -- | 0.6218 | 1,492,308.00 | -25.92 | -24.31 | -37.79 | -30.77 | -77.32 | -- | -4,018.56 | -2,817.04 | -- | -6.50 | 0.7028 | -- | 362.81 | 44.46 | -10.78 | -- | 19.31 | -- |
| Jiangsu Recbio Technology Co Ltd | 2.22m | -133.44m | 414.68m | 507.00 | -- | 11.22 | -- | 186.44 | -1.55 | -1.55 | 0.0258 | 0.4234 | 0.006 | -- | -- | 23,172.20 | -36.26 | -31.31 | -64.03 | -37.31 | -- | -- | -5,990.59 | -- | 0.2767 | -100.74 | 0.8254 | -- | -- | -- | 1.67 | -- | 16.82 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Australian Ethical Investments Ltd. (Investment Management)as of 25 Sep 2025 | 15.50m | 9.02% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 3.24m | 1.89% |
| Mutual Trust Pty Ltd.as of 30 Jun 2024 | 1.13m | 0.66% |
| FIL Pensions Managementas of 30 Jun 2025 | 1.06m | 0.62% |
| DFA Australia Ltd.as of 31 Dec 2025 | 764.34k | 0.45% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 381.84k | 0.22% |
| BetaShares Capital Ltd.as of 31 Dec 2025 | 373.61k | 0.22% |
| Mandarine Gestion SAas of 30 Jun 2025 | 100.00k | 0.06% |
| Lazard Asset Management LLCas of 31 Jan 2026 | 75.82k | 0.04% |
| Mercer Global Investments Europe Ltd.as of 30 Jun 2025 | 65.68k | 0.04% |
